Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ondansetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.98 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.98 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.98 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.98 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.98 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.98 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.98 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ondansetron SCHEMBL17076602 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL29607040 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (S)-Ondansetron SCHEMBL25017 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL123389 | 1.00 | CYP3A4 (0.98) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL7217414 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL25018 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL8153849 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL29387592 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Ondansetron SCHEMBL27599152 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| (R)-Ondansetron SCHEMBL157565 | 0.99 | CYP3A4 (0.96) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6502 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4658240-A2 | PHARMACEUTICAL COMPOSITIONS FOR NASAL DELIVERY | Therakind Limited (GB) | 2025-12-10 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| CN-120053385-A | Ondansetron hydrochloride tablet and preparation method thereof | 福安药业集团宁波天衡制药有限公司 | 2025-05-30 | — | — | CN | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-5756514-A | Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists | LARIJANI GHASSEM E (US) | 1998-05-26 | — | — | US | claimed |
| US-5712302-A | TREATMENT OF CHEMOTHERAPY SIDE EFFECTS | SEPRACOR INC. (US) | 1998-01-27 | — | — | US | claimed |
| US-5629333-A | Method treating cognitive disorders using optically pure R(+) ondansetron | SEPRACOR INC. (US) | 1997-05-13 | — | — | US | claimed |
| US-5470868-A | Methods for treating emesis and nausea using optically pure R(+) ondansetron | SEPRACOR INC. (US) | 1995-11-28 | — | — | US | claimed |
| EP-0591434-A4 | METHOD AND COMPOSITIONS FOR TREATING EMESIS, NAUSEA AND OTHER DISORDERS USING OPTICALLY PURE R(+) ONDANSETRON | SEPRACOR INC (US) | 1994-09-14 | — | — | EP | claimed |
| EP-0591395-A4 | — | — | 1994-08-31 | — | — | EP | claimed |
| EP-0591395-A1 | METHODS AND COMPOSITIONS FOR TREATING EMESIS, NAUSEA AND OTHER DISORDERS USING OPTICALLY PURE S(-) ONDANSETRON | SEPRACOR, INC. (US) | 1994-04-13 | — | — | EP | claimed |
| EP-0591434-A1 | METHOD AND COMPOSITIONS FOR TREATING EMESIS, NAUSEA AND OTHER DISORDERS USING OPTICALLY PURE R(+) ONDANSETRON | SEPRACOR, INC. (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000074-A1 | METHOD AND COMPOSITIONS FOR TREATING EMESIS, NAUSEA AND OTHER DISORDERS USING OPTICALLY PURE R(+) ONDANSETRON | SEPRACOR, INC. (US) | 1993-01-07 | — | — | WO | claimed |
| WO-1993000075-A1 | METHODS AND COMPOSITIONS FOR TREATING EMESIS, NAUSEA AND OTHER DISORDERS USING OPTICALLY PURE S(-) ONDANSETRON | SEPRACOR, INC. (US) | 1993-01-07 | — | — | WO | claimed |